Mesoblast's long-term protection
Wednesday, 16 July, 2008
Mesoblast [ASX: MSB] has been granted a US patent through to 2019 for its Mesenchymal Precursor Cells [MPC], proprietary adult stem cells developed by Mesoblast and its sister company Angioblast Systems.
The patent ensures only Mesoblast and Angioblast can commercialise MPCs in the US.
MPCs were first identified in Australia, at the Hanson Institute in Adelaide. They are capable of repairing and regenerating a host of tissue types, including bone, cartilage, fat, blood vessels and heart muscle.
Farm animals and aquaculture cryopreservation partnership announced
Vitrafy Life Sciences Limited has announced that it has entered a 12-month exclusive agreement...
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
